Want to see TSE:HEAL full AI Analyst Report?
HEAL Stock Chart & Stats
C$0.08
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.08
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.07 - C$0.14
Previous CloseN/A
Volume3.00K
Average Volume (3M)3.65K
Market Cap
C$4.28M
Enterprise ValueC$2.50M
Total Cash (Recent Filing)C$1.19M
Total Debt (Recent Filing)C$354.09K
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding61,077,354
10 Day Avg. Volume5,146
30 Day Avg. Volume3,650
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.29
Price to Sales (P/S)0.00
P/FCF Ratio-5.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved 2025 Balance SheetThe return to positive equity and modest leverage improves financial resilience versus 2023–2024. If maintained, this gives Restart greater flexibility to fund development and withstand operating losses.
Reduced Cash BurnAlthough cash flow remains negative, the reduction in outflow magnitude indicates some improvement in cash discipline or spending levels. Sustained improvement could extend the company’s funding runway over the medium term.
Rebuilding Asset BaseA larger asset base may support future research, development, or commercialization activities. This provides a foundation for operating expansion, although the assets have not yet translated into recurring revenue or profitability.
Bears Say
No Recurring RevenueThe absence of recurring revenue shows that the business has not established commercial traction or a dependable customer base. This limits operating self-sufficiency and makes future funding dependent on uncertain development outcomes.
Persistent Operating LossesPersistent operating losses indicate that the current business model is not yet economically viable. Without revenue growth and improved margins, the company may continue consuming capital before reaching sustainable profitability.
Ongoing External Funding NeedContinued negative operating and free cash flow means internal cash generation is insufficient to fund operations. Reliance on external capital can create dilution, financing risk, and execution constraints over the next several months.
Restart Life Sciences News
HEAL FAQ
What was Restart Life Sciences’s price range in the past 12 months?
Restart Life Sciences lowest stock price was C$0.07 and its highest was C$0.14 in the past 12 months.
What is Restart Life Sciences’s market cap?
Restart Life Sciences’s market cap is C$4.28M.
When is Restart Life Sciences’s upcoming earnings report date?
Restart Life Sciences’s upcoming earnings report date is Aug 21, 2026 which is in 2 days.
How were Restart Life Sciences’s earnings last quarter?
Currently, no data Available
Is Restart Life Sciences overvalued?
According to Wall Street analysts Restart Life Sciences’s price is currently Overvalued.
Does Restart Life Sciences pay dividends?
Restart Life Sciences does not currently pay dividends.
What is Restart Life Sciences’s EPS estimate?
Restart Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Restart Life Sciences have?
Restart Life Sciences has 61,077,354 shares outstanding.
What happened to Restart Life Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Restart Life Sciences?
Currently, no hedge funds are holding shares in TSE:HEAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Restart Life Sciences
Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.